These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. RORα contributes to the maintenance of genome ploidy in the liver of mice with diet-induced nonalcoholic steatohepatitis. Kim JY; Yang IS; Kim HJ; Yoon JY; Han YH; Seong JK; Lee MO Am J Physiol Endocrinol Metab; 2022 Feb; 322(2):E118-E131. PubMed ID: 34894722 [TBL] [Abstract][Full Text] [Related]
3. Unique features associated with hepatic oxidative DNA damage and DNA methylation in non-alcoholic fatty liver disease. Nishida N; Yada N; Hagiwara S; Sakurai T; Kitano M; Kudo M J Gastroenterol Hepatol; 2016 Sep; 31(9):1646-53. PubMed ID: 26875698 [TBL] [Abstract][Full Text] [Related]
4. Necroptosis is a key pathogenic event in human and experimental murine models of non-alcoholic steatohepatitis. Afonso MB; Rodrigues PM; Carvalho T; Caridade M; Borralho P; Cortez-Pinto H; Castro RE; Rodrigues CM Clin Sci (Lond); 2015 Oct; 129(8):721-39. PubMed ID: 26201023 [TBL] [Abstract][Full Text] [Related]
5. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice. Tessitore A; Cicciarelli G; Del Vecchio F; Gaggiano A; Verzella D; Fischietti M; Mastroiaco V; Vetuschi A; Sferra R; Barnabei R; Capece D; Zazzeroni F; Alesse E BMC Cancer; 2016 Jan; 16():3. PubMed ID: 26728044 [TBL] [Abstract][Full Text] [Related]
6. Apoptosis and non-alcoholic fatty liver diseases. Kanda T; Matsuoka S; Yamazaki M; Shibata T; Nirei K; Takahashi H; Kaneko T; Fujisawa M; Higuchi T; Nakamura H; Matsumoto N; Yamagami H; Ogawa M; Imazu H; Kuroda K; Moriyama M World J Gastroenterol; 2018 Jul; 24(25):2661-2672. PubMed ID: 29991872 [TBL] [Abstract][Full Text] [Related]
7. Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study. Nakamura N; Hatano E; Iguchi K; Sato M; Kawaguchi H; Ohtsu I; Sakurai T; Aizawa N; Iijima H; Nishiguchi S; Tomono T; Okuda Y; Wada S; Seo S; Taura K; Uemoto S; Ikegawa M BMC Cancer; 2019 Jun; 19(1):621. PubMed ID: 31238892 [TBL] [Abstract][Full Text] [Related]
8. Peroxisomal β-oxidation regulates whole body metabolism, inflammatory vigor, and pathogenesis of nonalcoholic fatty liver disease. Moreno-Fernandez ME; Giles DA; Stankiewicz TE; Sheridan R; Karns R; Cappelletti M; Lampe K; Mukherjee R; Sina C; Sallese A; Bridges JP; Hogan SP; Aronow BJ; Hoebe K; Divanovic S JCI Insight; 2018 Mar; 3(6):. PubMed ID: 29563328 [TBL] [Abstract][Full Text] [Related]
9. Molecular profiling of nonalcoholic fatty liver disease-associated hepatocellular carcinoma using SB transposon mutagenesis. Kodama T; Yi J; Newberg JY; Tien JC; Wu H; Finegold MJ; Kodama M; Wei Z; Tamura T; Takehara T; Johnson RL; Jenkins NA; Copeland NG Proc Natl Acad Sci U S A; 2018 Oct; 115(44):E10417-E10426. PubMed ID: 30327349 [TBL] [Abstract][Full Text] [Related]
10. Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play. Charrez B; Qiao L; Hebbard L World J Gastroenterol; 2016 Feb; 22(8):2494-502. PubMed ID: 26937137 [TBL] [Abstract][Full Text] [Related]
11. Nonalcoholic fatty liver disease promotes hepatocellular carcinoma through direct and indirect effects on hepatocytes. Ma C; Zhang Q; Greten TF FEBS J; 2018 Feb; 285(4):752-762. PubMed ID: 28857485 [TBL] [Abstract][Full Text] [Related]
12. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice. Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675 [TBL] [Abstract][Full Text] [Related]
14. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Takahashi Y; Fukusato T World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438 [TBL] [Abstract][Full Text] [Related]
15. Liver polyploidy: Dr Jekyll or Mr Hide? Gentric G; Desdouets C Oncotarget; 2015 Apr; 6(11):8430-1. PubMed ID: 25940698 [No Abstract] [Full Text] [Related]
16. TAZ-induced Cybb contributes to liver tumor formation in non-alcoholic steatohepatitis. Wang X; Zeldin S; Shi H; Zhu C; Saito Y; Corey KE; Osganian SA; Remotti HE; Verna EC; Pajvani UB; Schwabe RF; Tabas I J Hepatol; 2022 Apr; 76(4):910-920. PubMed ID: 34902531 [TBL] [Abstract][Full Text] [Related]
17. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Salomao M; Yu WM; Brown RS; Emond JC; Lefkowitch JH Am J Surg Pathol; 2010 Nov; 34(11):1630-6. PubMed ID: 20975341 [TBL] [Abstract][Full Text] [Related]
18. Demethyleneberberine attenuates non-alcoholic fatty liver disease with activation of AMPK and inhibition of oxidative stress. Qiang X; Xu L; Zhang M; Zhang P; Wang Y; Wang Y; Zhao Z; Chen H; Liu X; Zhang Y Biochem Biophys Res Commun; 2016 Apr; 472(4):603-9. PubMed ID: 26970305 [TBL] [Abstract][Full Text] [Related]
19. Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development. Jiang CM; Pu CW; Hou YH; Chen Z; Alanazy M; Hebbard L World J Gastroenterol; 2014 Nov; 20(44):16464-73. PubMed ID: 25469014 [TBL] [Abstract][Full Text] [Related]